Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. - Wikidata - wikimedia - TriplyDB

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

http://www.wikidata.org/entity/Q37721802

about

Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate Tamoxifen Resistance: Emerging Molecular Targets The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus Revealing the Complexity of Breast Cancer by Next Generation Sequencing Optimal management of hormone receptor positive metastatic breast cancer in 2016 Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?Antiestrogens: structure-activity relationships and use in breast cancer treatment Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.Precision medicine in breast cancer: reality or utopia?Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.Estrogen receptor mutations and their role in breast cancer progression Targeted therapies for ER+/HER2- metastatic breast cancer.Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers.Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients A decision support framework for genomically informed investigational cancer therapy.Clinical next generation sequencing to identify actionable aberrations in a phase I program.The changing role of ER in endocrine resistance.Endocrine resistance in breast cancer--An overview and update.Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.

P2860

Q24273274-1B27665A-E6FD-4A98-9ACA-812CEDFA36DA Q26739969-AC721962-3D27-4612-A917-5AAC0446B0E3 Q26740184-02110BB0-74AF-44B2-A3F0-0C4F46D23C93 Q26777395-D9DA5752-5731-4D81-BBF3-16E91DC94413 Q26777683-30A62D5F-AD7B-4BD2-B107-19FF1F9FD981 Q28069856-DE7F71E8-5C1C-447A-8FF0-E4CD7D92F063 Q28074060-6B609B13-EFA9-4302-A7C8-9C3EDF86C7CC Q28077245-A9EDC37A-E983-41BB-859E-DFCC8DFBBEC2 Q30239901-A6349DA9-6B28-47AC-BAF5-1CBBFE627DE0 Q30372977-567961C0-AC00-4DA8-8900-6A95F1DC1D57 Q33722765-4FECFCF1-0B38-4FEC-9739-538F9405C30F Q33806957-38807069-2408-43F7-875C-7AE491B87ADE Q33809114-C9FDEF3D-D767-4FDC-8F12-A064176CB4A3 Q33819404-3F8FD64A-D218-4FCB-8A11-280051845368 Q33903949-28E41569-F484-431A-A35A-8FF31CA5C3B2 Q34315889-39CD76AF-4CCC-4A8B-8D6A-3AAE05B1FD99 Q34484414-93CC88E7-C6EC-41DD-BA09-9C1CEA968FE7 Q34534031-EE59E00F-C6C9-479E-AC30-4C26E66D1B2D Q34708926-A47A4805-3E27-4549-96C7-B88956D6549B Q34736075-2755D269-AB5E-4201-8BBF-A222E58BE945 Q35025646-1F478E8E-8747-4203-80BB-2E350E75645C Q35159751-6AEA54E7-36B6-4B5A-91C6-1126254246CC Q35599448-725DCDDF-8149-4815-8A71-B85339F0D71F Q35658860-7BA8658C-5064-4FF5-9057-B3821CEE94A6 Q35763853-6724A805-E9AF-464D-B168-91001B958600 Q36011096-58F18667-CB76-4E64-9FD7-3998B4904A86 Q36022154-A00A516F-769D-43A6-9E86-8476B41F15F5 Q36047387-9649E6D6-77A8-4F2B-AB04-B56EC26B31B2 Q36064901-7867FA82-008C-4E8F-A64B-D5AF95DA6525 Q36279700-6C5C863E-4B68-4A70-8367-1267FC617365 Q36288939-8B82BD3F-B8D7-40D8-B42A-FA53F08F27C6 Q36294743-1DD3BCB1-10B2-454B-ACBB-392632DBFC09 Q36299589-FCFC7199-1A9C-4606-9115-0E21C2EEC82E Q36336601-597A1169-A00B-45BB-BBFF-EDA8FA1381B1 Q36386322-FFAFD0A8-83F6-4CCA-B518-8DAE8394D30C Q36450456-B76F7A05-D3A8-4D5B-ADC0-C7095883525B Q36545690-7D37C2D5-DD4C-4B51-8993-5BE30E79EAEA Q36598699-6E570E87-01FE-45E7-822E-F8F69E721CDB Q36642923-E8F4B995-BCF5-44D1-AC75-2AE7DB2DED92 Q36768079-30CF18D7-6D89-452D-84B6-251778424EC7

P2860

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

http://www.wikidata.org/entity/Q37721802

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emergence of constitutively ac ...... ceptor-positive breast cancer.

@en

Emergence of constitutively ac ...... ceptor-positive breast cancer.

@nl

type

label

Emergence of constitutively ac ...... ceptor-positive breast cancer.

@en

Emergence of constitutively ac ...... ceptor-positive breast cancer.

@nl

prefLabel

Emergence of constitutively ac ...... ceptor-positive breast cancer.

@en

Emergence of constitutively ac ...... ceptor-positive breast cancer.

@nl

P1433

Q37721802-C252B487-D47A-427B-8322-4E0A1452EFB9

P1476

Q37721802-B9AA4813-6799-49AB-9B9A-40C97CC5108A

P2093

Q37721802-0CFD3C53-B0B6-44C7-99A7-53036108221F

Q37721802-18C25D80-8DC4-4DDB-8C88-1B239E6AF010

Q37721802-288F295A-1531-41A8-9E79-0D199047A249

Q37721802-2BC9CB89-731F-471B-94E5-C123AC92F9CB

Q37721802-2FD44B59-2603-48E4-B33F-402D211D7B74

Q37721802-3B7D518D-3E55-429F-B4D7-75138F26502E

Q37721802-4217174B-6284-4C54-B4DE-C75A85038434

Q37721802-424092F5-A63B-49D3-AAF3-7B74F99EE59D

Q37721802-53C1D6D9-0404-447E-A08B-F93976F10A6A

Q37721802-5A8A6306-8B9F-43FE-BB62-BA167917210E

P2860

Q37721802-00FE5E59-3F19-435D-B8DC-0C83E87FEB4B

Q37721802-190D6423-60F1-4D4D-8878-1054264D86C0

Q37721802-1AEB3DC9-E4A7-4A4B-BFE2-D33229DBB1E0

Q37721802-1D10B671-E75D-4036-82EA-B8639747FE2E

Q37721802-25111CCE-B7ED-49D9-92E9-3995BE7EF1FF

Q37721802-2C299BED-3346-4325-AF4D-2E814FA021F5

Q37721802-2E9E0C98-9974-4DEB-93CE-E9A5167C119A

Q37721802-35A1C10A-7FCD-4F56-AE88-E295849A50F4

Q37721802-39427283-F416-456F-924D-AD1E3EAC7840

Q37721802-395729B6-B829-4FAA-BCAD-175C2D2DDDB9

P304

Q37721802-1DFC87D4-AC6D-4B5D-9E9B-BDA68D9C1037

P31

Q37721802-FF929421-AA92-4F35-BE6B-D5E5A3ABC56A

P356

Q37721802-8975E1A2-4BA4-4407-B9CF-51C8DC66B721

P407

Q37721802-9535484A-3F55-45E0-A5F0-067E08B2B752

P433

Q37721802-1581B49F-3817-4E85-988E-08EA1832D02B

P478

Q37721802-8BA89D66-F403-4F50-A69E-30D1211ED889

P50

Q37721802-2106D65E-95BD-4FA3-A6CA-C20669B053C6

Q37721802-3FB5A84D-2FC1-4F14-834F-F1245E8FFF23

Q37721802-57737E84-6285-42E5-B097-D8F4B16C5C0D

Q37721802-BF4B72A4-D452-40A5-B899-C57E4461E574

P577

Q37721802-FB1D8C61-F173-45E8-8E25-125613FCF256

P698

Q37721802-2CD990B9-0042-4356-8645-F76D67544928

P921

Q37721802-F2D82F10-B230-440F-BAA6-64893FF5ECF0

P932

Q37721802-1FD8BB38-D03E-4CED-B75B-0D3070740DAE

P356

1078-0432.CCR-13-2332

P1433

Clinical Cancer Research

P1476

Emergence of constitutively ac ...... ceptor-positive breast cancer.

@en

P2093

Addie Dvir

http://www.w3.org/2001/XMLSchema#string

Ana Maria Gonzalez-Angulo

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Doron Lipson

http://www.w3.org/2001/XMLSchema#string

Garrett Frampton

http://www.w3.org/2001/XMLSchema#string

Geoff Otto

http://www.w3.org/2001/XMLSchema#string

Gilles Buchwalter

http://www.w3.org/2001/XMLSchema#string

Ido Wolf

http://www.w3.org/2001/XMLSchema#string

Jaime Ferrer-Lozano

http://www.w3.org/2001/XMLSchema#string

James Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

Comprehensive molecular portraits of human breast tumours

Fast and accurate short read alignment with Burrows-Wheeler transform

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

The Sequence Alignment/Map format and SAMtools

Whole-genome analysis informs breast cancer response to aromatase inhibition

How to apply de Bruijn graphs to genome assembly

P304

1757-1767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-2332

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Henry Leonidas Gomez

Funda Meric-Bernstam

Justin M. Balko

P577

2014-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24398047

http://www.w3.org/2001/XMLSchema#string

P921

estrogen-receptor positive breast cancer

P932

3998833

http://www.w3.org/2001/XMLSchema#string